Biogen Inc. (NASDAQ:BIIB) Receives $230.14 Consensus PT from Analysts

Biogen Inc. (NASDAQ:BIIB) has been assigned an average recommendation of “Moderate Buy” from the thirty-three research firms that are covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, thirteen have given a hold recommendation, eighteen have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $230.1429.

Several brokerages recently issued reports on BIIB. Piper Sandler reiterated an “overweight” rating and issued a $245.00 price target (up from $225.00) on shares of Biogen in a research note on Thursday, September 3rd. Bank of America reduced their target price on Biogen from $217.00 to $215.00 and set a “neutral” rating on the stock in a report on Tuesday, July 21st. Guggenheim boosted their price target on Biogen from $260.00 to $280.00 and gave the company a “buy” rating in a research note on Tuesday, July 21st. Cantor Fitzgerald reiterated an “overweight” rating on shares of Biogen in a research note on Monday, June 22nd. Finally, Needham & Company LLC raised their target price on shares of Biogen from $255.00 to $256.00 and gave the company a “buy” rating in a report on Monday, June 29th.

Institutional Trading of Biogen

Several large investors have recently made changes to their positions in the company. Tidal Investments LLC increased its stake in Biogen by 9.0% in the second quarter. Tidal Investments LLC now owns 63,842 shares of the biotechnology company’s stock valued at $13,794,000 after acquiring an additional 5,256 shares during the last quarter. National Pension Service lifted its stake in Biogen by 1.1% during the second quarter. National Pension Service now owns 406,064 shares of the biotechnology company’s stock worth $87,734,000 after purchasing an additional 4,397 shares during the last quarter. Integrated Wealth Concepts LLC boosted its holdings in shares of Biogen by 23.8% in the 2nd quarter. Integrated Wealth Concepts LLC now owns 9,426 shares of the biotechnology company’s stock valued at $2,037,000 after purchasing an additional 1,810 shares in the last quarter. NewEdge Advisors LLC boosted its holdings in shares of Biogen by 15.4% in the 2nd quarter. NewEdge Advisors LLC now owns 15,037 shares of the biotechnology company’s stock valued at $3,249,000 after purchasing an additional 2,006 shares in the last quarter. Finally, IFP Advisors Inc increased its stake in shares of Biogen by 28.5% in the 2nd quarter. IFP Advisors Inc now owns 1,479 shares of the biotechnology company’s stock valued at $320,000 after purchasing an additional 328 shares during the last quarter. Institutional investors and hedge funds own 87.93% of the company’s stock.

Biogen Price Performance

NASDAQ:BIIB opened at $219.05 on Tuesday. Biogen has a 52 week low of $135.39 and a 52 week high of $225.80. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.26 and a current ratio of 1.87. The firm’s 50-day simple moving average is $210.68 and its 200 day simple moving average is $198.10. The firm has a market cap of $32.36 billion, a price-to-earnings ratio of 38.77, a P/E/G ratio of 2.39 and a beta of 0.17.

Biogen (NASDAQ:BIIB) last posted its quarterly earnings data on Wednesday, July 29th. The biotechnology company reported $3.60 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.94 by $0.66. Biogen had a net margin of 8.32% and a return on equity of 11.18%. The firm had revenue of $2.74 billion during the quarter, compared to the consensus estimate of $2.46 billion. During the same quarter in the previous year, the firm posted $5.47 EPS. The business’s revenue for the quarter was up 3.4% compared to the same quarter last year. Biogen has set its FY 2026 guidance at 12.000-13.000 EPS. As a group, sell-side analysts predict that Biogen will post 12.41 earnings per share for the current year.

Biogen Company Profile

Biogen Inc is a biotechnology company focused on discovering, developing and commercializing therapies for neurological and neurodegenerative diseases. Founded in 1978, the company is headquartered in Cambridge, Massachusetts, and serves patients and healthcare providers in markets around the world.

Biogen’s portfolio includes treatments for multiple sclerosis, including Tecfidera, Vumerity, Tysabri, Avonex and Plegridy, as well as Spinraza for spinal muscular atrophy, developed in collaboration with Ionis Pharmaceuticals.